Mononuclear cell infiltration in clear‐cell renal cell carcinoma independently predicts patient survival
Open Access
- 17 May 2006
- Vol. 107 (1) , 46-53
- https://doi.org/10.1002/cncr.21951
Abstract
BACKGROUND The impact of mononuclear cell infiltration on renal cell carcinoma (RCC) biology has been controversial, previously reported to be associated with either a favorable or unfavorable prognosis. The objective of the current study was to evaluate associations between mononuclear cell infiltration in routinely prepared paraffin‐embedded specimens with survival in patients with clear‐cell RCC. METHODS A total of 306 patients were identified treated with nephrectomy for clear‐cell RCC between 1990 and 1994. A single urologic pathologist, blinded to patient outcome, reviewed the specimens and quantified the extent of mononuclear cell infiltration as absent, focal, moderate, or marked. Cancer‐specific survival was estimated using the Kaplan–Meier method. Associations of mononuclear cell infiltration with death from RCC were assessed using Cox proportional hazards regression models. RESULTS At last follow‐up, 173 of the 306 patients studied had died, including 96 patients who died from RCC. Mononuclear cell infiltration was absent in 165 (54%), focal in 70 (23%), moderate in 53 (17%), and marked in 18 (6%). Univariately, patients with specimens that had mononuclear cell infiltration were over 2 times more likely to die from RCC compared with patients whose specimens exhibited no mononuclear cell infiltration (risk ratio, 2.63; P<.001). After adjusting for the Mayo Clinic SSIGN (stage, size, grade, and necrosis) score, patients with specimens that had mononuclear cell infiltration exhibited a significantly increased likelihood of dying from RCC compared with patients whose specimens had no mononuclear cell infiltration (risk ratio, 1.61; P = .028). CONCLUSIONS Mononuclear cell infiltration is associated with death from RCC even after multivariate adjustment. Routine documentation of mononuclear cell infiltration is recommended during the pathologic assessment of RCC. Cancer 2006. © 2006 American Cancer Society.Keywords
This publication has 31 references indexed in Scilit:
- The preoperative erythrocyte sedimentation rate is an independent prognostic factor in renal cell carcinomaCancer, 2005
- Investigating the Potential of Bevacizumab in Other Indications: Metastatic Renal Cell, Non-Small Cell Lung, Pancreatic and Breast CancerOncology, 2005
- Costimulatory molecule B7‐H1 in primary and metastatic clear cell renal cell carcinomaCancer, 2005
- Histologic coagulative tumor necrosis as a prognostic indicator of renal cell carcinoma aggressivenessCancer, 2005
- Cancer Statistics, 2005CA: A Cancer Journal for Clinicians, 2005
- Update on the Role of Interleukin 2 and Other Cytokines in the Treatment of Patients with Stage IV Renal CarcinomaClinical Cancer Research, 2004
- Clinical responses following nonmyeloablative allogeneic stem cell transplantation for renal cell carcinoma are associated with expansion of CD8+ IFN-γ-producing T cellsBone Marrow Transplantation, 2004
- A Randomized Trial of Bevacizumab, an Anti–Vascular Endothelial Growth Factor Antibody, for Metastatic Renal CancerNew England Journal of Medicine, 2003
- Intratumoral T Cells, Recurrence, and Survival in Epithelial Ovarian CancerNew England Journal of Medicine, 2003
- An Outcome Prediction Model for Patients with Clear Cell Renal Cell Carcinoma Treated with Radical Nephrectomy Based on Tumor Stage, Size, Grade and Necrosis: The Ssign ScoreJournal of Urology, 2002